Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients
Primary chemotherapy for breast cancer is effective as postoperative adjuvant therapy. However, one of the critical disadvantages was a treatment delay for patients with progressive disease. The present study attempts to clarify quantitative parameters on MRI which can be used to predict the sensiti...
Gespeichert in:
| Veröffentlicht in: | European journal of radiology 2006-11, Vol.60 (2), p.270-274 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 274 |
|---|---|
| container_issue | 2 |
| container_start_page | 270 |
| container_title | European journal of radiology |
| container_volume | 60 |
| creator | Nagashima, Takeshi Sakakibara, Masahiro Nakamura, Rikiya Arai, Manabu Kadowaki, Masami Kazama, Toshiki Nakatani, Yukio Koda, Keiji Miyazaki, Masaru |
| description | Primary chemotherapy for breast cancer is effective as postoperative adjuvant therapy. However, one of the critical disadvantages was a treatment delay for patients with progressive disease. The present study attempts to clarify quantitative parameters on MRI which can be used to predict the sensitivity to treatment in breast cancer patients.
The subjects consisted of 26 patients with invasive ductal breast cancer who received primary chemotherapy before surgery. The mean maximum tumor dimension was 3.3
cm, and 21 cases had nodal involvements. Three cases demonstrated histological grade 3. Dynamic enhanced MRI was evaluated at three different time periods; prior to, in the midst of preoperative chemotherapy, and just before the initial operation. The signal intensity ratio (SIR) and early contrast uptake (ECU) were calculated, as well as the correlation between these dynamic data and the tumor reduction rates were analyzed retrospectively.
P-values of less than 0.05 were considered to indicate statistically significant.
Responders to chemotherapy had the significantly higher SIR and ECU values than non-responders (
p
=
0.0454 and 0.0334, respectively). ECU value significantly decreased as tumor reduction by chemotherapy (
p
=
0.0028). Pathological tumor dimension was significantly correlated with the tumor size estimated on presurgical MRI (
p
<
0.0001).
Our current series demonstrated the significant correlation between pretreatment MRI data and tumor reduction by chemotherapy in breast cancer patients. With these results, it seems possible to define good and non-responders prior to treatment. |
| doi_str_mv | 10.1016/j.ejrad.2006.07.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69005721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0720048X06002956</els_id><sourcerecordid>69005721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-e8e2509fdd31e8982863cb97dde24f387691c53e4a1b412a654d8cf9bf6370063</originalsourceid><addsrcrecordid>eNp90MtqGzEUgGFRWmInzRMUymza3Ux1G10WWYQ0qQ0JgdBAdkIjnSEynhlXkgN--8ixwbuutPnPQedD6BvBDcFE_Fo1sIrWNxRj0WDZYMI_oTlRktZSUvkZzbGkuMZcvczQeUorjHHLNT1DMyI0FVjqOVr83o12CK6C8dWODnz18LSsNhF8cDlV7hWGKcGYQg5vIe-qMFZdBJty5fZ5rDY2Bxhz-oq-9Had4PL4XqDnu9u_N4v6_vHP8ub6vna8ZbkGBbTFuveeEVBaUSWY67T0HijvmZJCE9cy4JZ0nFArWu6V63XXCybLoewC_Tzs3cTp3xZSNkNIDtZrO8K0TUbocqWkpITsELo4pRShN5sYBht3hmCzBzQr8wFo9oAGS1MAy9T34_ptN4A_zRzFSvDjGNjk7LqPhSGkU6eo4ILR0l0dOigYbwGiSa5AFeEQwWXjp_Dfj7wDLsmPPw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69005721</pqid></control><display><type>article</type><title>Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Nagashima, Takeshi ; Sakakibara, Masahiro ; Nakamura, Rikiya ; Arai, Manabu ; Kadowaki, Masami ; Kazama, Toshiki ; Nakatani, Yukio ; Koda, Keiji ; Miyazaki, Masaru</creator><creatorcontrib>Nagashima, Takeshi ; Sakakibara, Masahiro ; Nakamura, Rikiya ; Arai, Manabu ; Kadowaki, Masami ; Kazama, Toshiki ; Nakatani, Yukio ; Koda, Keiji ; Miyazaki, Masaru</creatorcontrib><description>Primary chemotherapy for breast cancer is effective as postoperative adjuvant therapy. However, one of the critical disadvantages was a treatment delay for patients with progressive disease. The present study attempts to clarify quantitative parameters on MRI which can be used to predict the sensitivity to treatment in breast cancer patients.
The subjects consisted of 26 patients with invasive ductal breast cancer who received primary chemotherapy before surgery. The mean maximum tumor dimension was 3.3
cm, and 21 cases had nodal involvements. Three cases demonstrated histological grade 3. Dynamic enhanced MRI was evaluated at three different time periods; prior to, in the midst of preoperative chemotherapy, and just before the initial operation. The signal intensity ratio (SIR) and early contrast uptake (ECU) were calculated, as well as the correlation between these dynamic data and the tumor reduction rates were analyzed retrospectively.
P-values of less than 0.05 were considered to indicate statistically significant.
Responders to chemotherapy had the significantly higher SIR and ECU values than non-responders (
p
=
0.0454 and 0.0334, respectively). ECU value significantly decreased as tumor reduction by chemotherapy (
p
=
0.0028). Pathological tumor dimension was significantly correlated with the tumor size estimated on presurgical MRI (
p
<
0.0001).
Our current series demonstrated the significant correlation between pretreatment MRI data and tumor reduction by chemotherapy in breast cancer patients. With these results, it seems possible to define good and non-responders prior to treatment.</description><identifier>ISSN: 0720-048X</identifier><identifier>EISSN: 1872-7727</identifier><identifier>DOI: 10.1016/j.ejrad.2006.07.014</identifier><identifier>PMID: 16926079</identifier><identifier>CODEN: EJRADR</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - biosynthesis ; Biomarkers, Tumor - blood ; Breast neoplasms ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Carcinoma ; Carcinoma, Ductal, Breast - drug therapy ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Ductal, Breast - surgery ; Chemotherapy ; Chemotherapy, Adjuvant ; Contrast Media - administration & dosage ; Contrast Media - metabolism ; Dynamic imaging ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Image Enhancement ; Magnetic Resonance Imaging ; Mammary gland diseases ; Mastectomy ; Medical sciences ; Middle Aged ; MRI ; Neoplasm Invasiveness ; Neoplasm Staging ; Neoplasm, Residual ; Predictive Value of Tests ; Receptor, ErbB-2 - biosynthesis ; Receptor, ErbB-2 - blood ; Sensitivity and Specificity ; Signal Processing, Computer-Assisted ; Treatment Outcome ; Tumors</subject><ispartof>European journal of radiology, 2006-11, Vol.60 (2), p.270-274</ispartof><rights>2006 Elsevier Ireland Ltd</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-e8e2509fdd31e8982863cb97dde24f387691c53e4a1b412a654d8cf9bf6370063</citedby><cites>FETCH-LOGICAL-c453t-e8e2509fdd31e8982863cb97dde24f387691c53e4a1b412a654d8cf9bf6370063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejrad.2006.07.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18264632$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16926079$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nagashima, Takeshi</creatorcontrib><creatorcontrib>Sakakibara, Masahiro</creatorcontrib><creatorcontrib>Nakamura, Rikiya</creatorcontrib><creatorcontrib>Arai, Manabu</creatorcontrib><creatorcontrib>Kadowaki, Masami</creatorcontrib><creatorcontrib>Kazama, Toshiki</creatorcontrib><creatorcontrib>Nakatani, Yukio</creatorcontrib><creatorcontrib>Koda, Keiji</creatorcontrib><creatorcontrib>Miyazaki, Masaru</creatorcontrib><title>Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients</title><title>European journal of radiology</title><addtitle>Eur J Radiol</addtitle><description>Primary chemotherapy for breast cancer is effective as postoperative adjuvant therapy. However, one of the critical disadvantages was a treatment delay for patients with progressive disease. The present study attempts to clarify quantitative parameters on MRI which can be used to predict the sensitivity to treatment in breast cancer patients.
The subjects consisted of 26 patients with invasive ductal breast cancer who received primary chemotherapy before surgery. The mean maximum tumor dimension was 3.3
cm, and 21 cases had nodal involvements. Three cases demonstrated histological grade 3. Dynamic enhanced MRI was evaluated at three different time periods; prior to, in the midst of preoperative chemotherapy, and just before the initial operation. The signal intensity ratio (SIR) and early contrast uptake (ECU) were calculated, as well as the correlation between these dynamic data and the tumor reduction rates were analyzed retrospectively.
P-values of less than 0.05 were considered to indicate statistically significant.
Responders to chemotherapy had the significantly higher SIR and ECU values than non-responders (
p
=
0.0454 and 0.0334, respectively). ECU value significantly decreased as tumor reduction by chemotherapy (
p
=
0.0028). Pathological tumor dimension was significantly correlated with the tumor size estimated on presurgical MRI (
p
<
0.0001).
Our current series demonstrated the significant correlation between pretreatment MRI data and tumor reduction by chemotherapy in breast cancer patients. With these results, it seems possible to define good and non-responders prior to treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Breast neoplasms</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Carcinoma</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Ductal, Breast - surgery</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Contrast Media - administration & dosage</subject><subject>Contrast Media - metabolism</subject><subject>Dynamic imaging</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Image Enhancement</subject><subject>Magnetic Resonance Imaging</subject><subject>Mammary gland diseases</subject><subject>Mastectomy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>MRI</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Neoplasm, Residual</subject><subject>Predictive Value of Tests</subject><subject>Receptor, ErbB-2 - biosynthesis</subject><subject>Receptor, ErbB-2 - blood</subject><subject>Sensitivity and Specificity</subject><subject>Signal Processing, Computer-Assisted</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0720-048X</issn><issn>1872-7727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90MtqGzEUgGFRWmInzRMUymza3Ux1G10WWYQ0qQ0JgdBAdkIjnSEynhlXkgN--8ixwbuutPnPQedD6BvBDcFE_Fo1sIrWNxRj0WDZYMI_oTlRktZSUvkZzbGkuMZcvczQeUorjHHLNT1DMyI0FVjqOVr83o12CK6C8dWODnz18LSsNhF8cDlV7hWGKcGYQg5vIe-qMFZdBJty5fZ5rDY2Bxhz-oq-9Had4PL4XqDnu9u_N4v6_vHP8ub6vna8ZbkGBbTFuveeEVBaUSWY67T0HijvmZJCE9cy4JZ0nFArWu6V63XXCybLoewC_Tzs3cTp3xZSNkNIDtZrO8K0TUbocqWkpITsELo4pRShN5sYBht3hmCzBzQr8wFo9oAGS1MAy9T34_ptN4A_zRzFSvDjGNjk7LqPhSGkU6eo4ILR0l0dOigYbwGiSa5AFeEQwWXjp_Dfj7wDLsmPPw</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Nagashima, Takeshi</creator><creator>Sakakibara, Masahiro</creator><creator>Nakamura, Rikiya</creator><creator>Arai, Manabu</creator><creator>Kadowaki, Masami</creator><creator>Kazama, Toshiki</creator><creator>Nakatani, Yukio</creator><creator>Koda, Keiji</creator><creator>Miyazaki, Masaru</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061101</creationdate><title>Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients</title><author>Nagashima, Takeshi ; Sakakibara, Masahiro ; Nakamura, Rikiya ; Arai, Manabu ; Kadowaki, Masami ; Kazama, Toshiki ; Nakatani, Yukio ; Koda, Keiji ; Miyazaki, Masaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-e8e2509fdd31e8982863cb97dde24f387691c53e4a1b412a654d8cf9bf6370063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Breast neoplasms</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Carcinoma</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Ductal, Breast - surgery</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Contrast Media - administration & dosage</topic><topic>Contrast Media - metabolism</topic><topic>Dynamic imaging</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Image Enhancement</topic><topic>Magnetic Resonance Imaging</topic><topic>Mammary gland diseases</topic><topic>Mastectomy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>MRI</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Neoplasm, Residual</topic><topic>Predictive Value of Tests</topic><topic>Receptor, ErbB-2 - biosynthesis</topic><topic>Receptor, ErbB-2 - blood</topic><topic>Sensitivity and Specificity</topic><topic>Signal Processing, Computer-Assisted</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nagashima, Takeshi</creatorcontrib><creatorcontrib>Sakakibara, Masahiro</creatorcontrib><creatorcontrib>Nakamura, Rikiya</creatorcontrib><creatorcontrib>Arai, Manabu</creatorcontrib><creatorcontrib>Kadowaki, Masami</creatorcontrib><creatorcontrib>Kazama, Toshiki</creatorcontrib><creatorcontrib>Nakatani, Yukio</creatorcontrib><creatorcontrib>Koda, Keiji</creatorcontrib><creatorcontrib>Miyazaki, Masaru</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nagashima, Takeshi</au><au>Sakakibara, Masahiro</au><au>Nakamura, Rikiya</au><au>Arai, Manabu</au><au>Kadowaki, Masami</au><au>Kazama, Toshiki</au><au>Nakatani, Yukio</au><au>Koda, Keiji</au><au>Miyazaki, Masaru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients</atitle><jtitle>European journal of radiology</jtitle><addtitle>Eur J Radiol</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>60</volume><issue>2</issue><spage>270</spage><epage>274</epage><pages>270-274</pages><issn>0720-048X</issn><eissn>1872-7727</eissn><coden>EJRADR</coden><abstract>Primary chemotherapy for breast cancer is effective as postoperative adjuvant therapy. However, one of the critical disadvantages was a treatment delay for patients with progressive disease. The present study attempts to clarify quantitative parameters on MRI which can be used to predict the sensitivity to treatment in breast cancer patients.
The subjects consisted of 26 patients with invasive ductal breast cancer who received primary chemotherapy before surgery. The mean maximum tumor dimension was 3.3
cm, and 21 cases had nodal involvements. Three cases demonstrated histological grade 3. Dynamic enhanced MRI was evaluated at three different time periods; prior to, in the midst of preoperative chemotherapy, and just before the initial operation. The signal intensity ratio (SIR) and early contrast uptake (ECU) were calculated, as well as the correlation between these dynamic data and the tumor reduction rates were analyzed retrospectively.
P-values of less than 0.05 were considered to indicate statistically significant.
Responders to chemotherapy had the significantly higher SIR and ECU values than non-responders (
p
=
0.0454 and 0.0334, respectively). ECU value significantly decreased as tumor reduction by chemotherapy (
p
=
0.0028). Pathological tumor dimension was significantly correlated with the tumor size estimated on presurgical MRI (
p
<
0.0001).
Our current series demonstrated the significant correlation between pretreatment MRI data and tumor reduction by chemotherapy in breast cancer patients. With these results, it seems possible to define good and non-responders prior to treatment.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>16926079</pmid><doi>10.1016/j.ejrad.2006.07.014</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0720-048X |
| ispartof | European journal of radiology, 2006-11, Vol.60 (2), p.270-274 |
| issn | 0720-048X 1872-7727 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69005721 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Biological and medical sciences Biomarkers, Tumor - biosynthesis Biomarkers, Tumor - blood Breast neoplasms Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms - surgery Carcinoma Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - surgery Chemotherapy Chemotherapy, Adjuvant Contrast Media - administration & dosage Contrast Media - metabolism Dynamic imaging Female Gynecology. Andrology. Obstetrics Humans Image Enhancement Magnetic Resonance Imaging Mammary gland diseases Mastectomy Medical sciences Middle Aged MRI Neoplasm Invasiveness Neoplasm Staging Neoplasm, Residual Predictive Value of Tests Receptor, ErbB-2 - biosynthesis Receptor, ErbB-2 - blood Sensitivity and Specificity Signal Processing, Computer-Assisted Treatment Outcome Tumors |
| title | Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T21%3A51%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dynamic%20enhanced%20MRI%20predicts%20chemosensitivity%20in%20breast%20cancer%20patients&rft.jtitle=European%20journal%20of%20radiology&rft.au=Nagashima,%20Takeshi&rft.date=2006-11-01&rft.volume=60&rft.issue=2&rft.spage=270&rft.epage=274&rft.pages=270-274&rft.issn=0720-048X&rft.eissn=1872-7727&rft.coden=EJRADR&rft_id=info:doi/10.1016/j.ejrad.2006.07.014&rft_dat=%3Cproquest_cross%3E69005721%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69005721&rft_id=info:pmid/16926079&rft_els_id=S0720048X06002956&rfr_iscdi=true |